OPKO HEALTH INC (OPK) Stock Price, Quote, News and Overview
NASDAQ:OPK - Nasdaq - US68375N1037 - Common Stock - Currency: USD
OPK Quote, Performance and Key Statistics
1.68
+0.01 (+0.6%)
The current stock price of OPK is 1.68 USD. In the past month the price increased by 12.75%. In the past year, price increased by 77.59%.
OPK Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| CI | THE CIGNA GROUP | 10.97 | 82.08B | ||
| CVS | CVS HEALTH CORP | 11.71 | 79.88B | ||
| LH | LABCORP HOLDINGS INC | 17.15 | 20.84B | ||
| DGX | QUEST DIAGNOSTICS INC | 19.1 | 19.12B | ||
| FMS | FRESENIUS MEDICAL CARE-ADR | 13.74 | 13.55B | ||
| BTSGU | BRIGHTSPRING HEALTH SERV - BTSG 6 3/4 02/01/27 | 148.77 | 12.18B | ||
| DVA | DAVITA INC | 14.99 | 11.68B | ||
| HIMS | HIMS & HERS HEALTH INC | 112 | 10.77B | ||
| CHE | CHEMED CORP | 23.84 | 8.18B | ||
| CRVL | CORVEL CORP | 25.97 | 5.57B | ||
| OPCH | OPTION CARE HEALTH INC | 26.89 | 5.45B | ||
| GH | GUARDANT HEALTH INC | N/A | 5.30B |
Related stock screener links
About OPK
Company Profile
OPKO Health, Inc. is a biopharmaceutical and diagnostics company, which engages in the provision of healthcare services. The company is headquartered in Miami, Florida and currently employs 3,930 full-time employees. The firm focuses on leveraging its discovery, development, and commercialization expertise and novel and proprietary technologies. Its segments include pharmaceutical and diagnostics. The pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain, Rayaldee product sales and its pharmaceutical research and development. The diagnostics segment primarily consists of point-of-care operations. Its pharmaceutical business features Rayaldee, a United States Food and Drug Administration (FDA) approved treatment for secondary hyperparathyroidism (SHPT) in adults with stage three or four chronic kidney disease (CKD) and vitamin D insufficiency, and Somatrogon (hGH-CTP), a once-weekly human growth hormone injection. Its NGENLA (somatrogon-ghla), is a once-weekly, human growth hormone analog indicated for treatment of pediatric patients aged three years and older.
Company Info
OPKO HEALTH INC
4400 Biscayne Blvd.
Miami FLORIDA 33137 US
CEO: Phillip Frost
Employees: 3930
Company Website: https://www.opko.com/
Investor Relations: https://www.opko.com/investors
Phone: 13055754181
OPKO HEALTH INC / OPK FAQ
What is the stock price of OPKO HEALTH INC today?
The current stock price of OPK is 1.68 USD. The price increased by 0.6% in the last trading session.
What is the ticker symbol for OPKO HEALTH INC stock?
The exchange symbol of OPKO HEALTH INC is OPK and it is listed on the Nasdaq exchange.
On which exchange is OPK stock listed?
OPK stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for OPKO HEALTH INC stock?
10 analysts have analysed OPK and the average price target is 4.04 USD. This implies a price increase of 140.33% is expected in the next year compared to the current price of 1.68. Check the OPKO HEALTH INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is OPKO HEALTH INC worth?
OPKO HEALTH INC (OPK) has a market capitalization of 1.15B USD. This makes OPK a Small Cap stock.
How many employees does OPKO HEALTH INC have?
OPKO HEALTH INC (OPK) currently has 3930 employees.
What are the support and resistance levels for OPKO HEALTH INC (OPK) stock?
OPKO HEALTH INC (OPK) has a support level at 1.52 and a resistance level at 1.69. Check the full technical report for a detailed analysis of OPK support and resistance levels.
Is OPKO HEALTH INC (OPK) expected to grow?
The Revenue of OPKO HEALTH INC (OPK) is expected to decline by -20.28% in the next year. Check the estimates tab for more information on the OPK EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy OPKO HEALTH INC (OPK) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of OPK, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of OPK, evaluating the profitability, health, valuation and growth aspects
- OPKO HEALTH INC (OPK) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- OPKO HEALTH INC (OPK) Sales and EPS estimates to see what analysts future expectations are.
- OPKO HEALTH INC (OPK) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- OPKO HEALTH INC (OPK) Insider and Institutional Ownership to learn about the owners and their transactions.
- OPKO HEALTH INC (OPK) Stock Chart to make your own analysis
- OPKO HEALTH INC (OPK) Latest news and press-releases to stay up to date.
Does OPKO HEALTH INC (OPK) stock pay dividends?
OPK does not pay a dividend.
When does OPKO HEALTH INC (OPK) report earnings?
OPKO HEALTH INC (OPK) will report earnings on 2025-02-27, after the market close.
What is the Price/Earnings (PE) ratio of OPKO HEALTH INC (OPK)?
OPKO HEALTH INC (OPK) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.31).
What is the Short Interest ratio of OPKO HEALTH INC (OPK) stock?
The outstanding short interest for OPKO HEALTH INC (OPK) is 28.55% of its float. Check the ownership tab for more information on the OPK short interest.
OPK Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to OPK. When comparing the yearly performance of all stocks, OPK is one of the better performing stocks in the market, outperforming 93.3% of all stocks.
OPK Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to OPK. While OPK seems to be doing ok healthwise, there are quite some concerns on its profitability.
OPK Financial Highlights
Over the last trailing twelve months OPK reported a non-GAAP Earnings per Share(EPS) of -0.31. The EPS decreased by -16.51% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -5.93% | ||
| ROE | -9.53% | ||
| Debt/Equity | 0.31 |
OPK Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 86% to OPK. The Buy consensus is the average rating of analysts ratings from 10 analysts.
For the next year, analysts expect an EPS growth of 24.48% and a revenue growth -20.28% for OPK